News Posts List
Clinical trial evaluating IMO-2055 in kidney cancer
03/04/2008
An on-going phase 2, stage A, trial in patients with renal cell carcinoma. At present, one patient continues to receive treatment in this phase 2 trial. The Company expects that final data from this trial will be available in the second or third quarter of 2008.
Smoking May Be Greater Kidney Cancer Risk Than Thought
03/04/2008
Pulling together data from 24 studies conducted since the 1960s, an international research team found that the risk of kidney cancer was 38 percent higher among people who had ever smoked versus those who had never picked up the habit.
Illinois Governor Proclaims March 2008 Kidney Cancer Awareness Month
03/03/2008
Rod Blagojevich, Governor of the State of Illinois, proclaims March as awareness month in support of public information campaign.
Keystone Programs for Collaborative Discovery Launch at Fox Chase
03/02/2008
The Keystone Program in Personalized Kidney Cancer Therapy to investigate the mechanisms of kidney cancer metastasis and to uncover the molecular signals that anticipate how a kidney tumor will respond to therapies in order to optimize therapy for individual patients.
Novartis kidney cancer drug clears key hurdle
02/28/2008
Late-stage, or Phase III trials of the drug were halted early after interim results showed significantly better survival in patients with advanced kidney cancer who received Everolimus compared to placebos.
Kidney Cancer Association founding member, Dr. Nicholas Vogelzang, named to advisory board
02/28/2008
Ambit Biosciences today announced the formation of clinical advisory boards that will help the company advance its drug candidates in development for the treatment of blood cancers and solid tumors. The first advisory board will be focused on hematology and oncology, and the second will focus on solid tumors. The boards will guide Ambit on the development and implementation of the company's clinical programs for its kinase inhibitors, including AC220 for acute myeloid leukemia (AML) and AC480 for solid tumors.
Study finds molecule that spurs angiogenesis
02/22/2008
U.S. scientists have found a metabolic regulatory molecule known as PGC-1alpha in mice that detects low oxygen and nutrient levels when circulation ceases and activates the formation of blood vessels. This discovery could bring about development of treatments for cancer.
Research by I. Peters and colleagues in gene therapy provides new insights
02/21/2008
Age, adiposity, and smoking are risk factors for the development of renal cell carcinoma.
New Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
02/20/2008
A breakthrough therapy shown to extend median overall survival of patients with metastatic (advanced) renal cell carcinoma (RCC), the most common form of kidney cancer,(1,2) has been approved by Health Canada.
New cancer statistics show a rise in cancer deaths in 2005 and an overall drop in the cancer death rate since 1990
02/20/2008
American Indians and Alaska Natives have the highest rate of kidney cancer cases and deaths from kidney cancer, the report also shows.
News Feed